November 12, 2026
Business

Brazil rejects Dr Reddy’s, Cipla GLP-1 generics on technical grounds(Soban News)

Brazil’s regulator Anvisa rejects DRL and Cipla’s generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality

​Brazil’s regulator Anvisa rejects DRL and Cipla’s generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality by Soban News (international And National News)

Related posts

HONOR launches X7c 5G in India at ₹14,999, available exclusively on Amazon – CNBC TV18

News-Soban-Admin

Wipro, Tech Mahindra outshine TCS, Infosys in weak Q3 for IT(Soban News)

News-Soban-Admin

UK superflu shows worsen symptoms with bile vomiting: Know why it is serious – Times of India(Soban News)

News-Soban-Admin

Leave a Comment